Trial backs routine node biopsy for melanoma

Patients with intermediate thickness and thick melanoma should now undergo sentinel node biopsy as standard practice, claims the author of a long-awaited and controversial study.

Results from the MSLT-I trial weigh into a 35-year debate over whether there is any survival benefit when routine sentinel node biopsy is used as part of first-line management of melanoma.

Biopsy-guided management was found to significantly reduce the risk of recurrence: 10-year disease-free survival rates were boosted from 65% to 71% in patients with intermediate